BOSTON SCIENTIFIC ACQUIRING BTG
Boston Scientific has reached an agreement on the terms of a recommended offer to acquire BTG plc., a United Kingdom-based company that develops and commercializes products used in minimally-invasive procedures, targeting vascular diseases and cancer, as well as acute care pharmaceuticals.
Under the terms of the transaction, holders of BTG’s common shares would receive cash consideration of 840 pence (U.S.$10.79) per share. The total cash consideration for 100 percent of BTG’s equity is approximately £3.3B, or U.S.$4.2B. The transaction is intended to be affected by way of an English court-sanctioned scheme of arrangement, and is expected to close in the first half of 2019, subject to receipt of required regulatory approvals and the approval of BTG’s shareholders and the U.K. court.
BTG has 1,600 employees globally, located in North America, Europe, Asia and Australia working for three key businesses, the largest of which is its Interventional Medicine portfolio which encompasses several peripheral interventional product lines.
The company’s Interventional Medicine business has a highly-differentiated vascular portfolio, including filters, crossing catheters, microfoam and the EKOS Endovascular System.
The EKOS system, in combination with clot-dissolving drugs, breaks down blood clots to restore blood flow in patients with pulmonary emboli, deep vein thrombosis and peripheral arterial occlusions.
It was the first device cleared by the Food and Drug Administration for the treatment of pulmonary embolism – a common complication of hospitalization and a leading cause of preventable hospital deaths.
The interventional oncology franchise includes the TheraSphere® Y-90 radiotherapy microspheres and the GALIL cryoablation system, used to treat patients with liver, kidney and other cancers.
More than 840,000 people were expected to be diagnosed with liver cancer in 2018, and that number is expected to grow to 1.1 million by 2030.i Kidney cancer is among the 10 most common cancers in both men and women.
The BTG portfolio also includes a pharmaceutical business comprised of acute care antidotes to treat overexposure to certain medications and toxins, and a licensing business that receives royalties relating to products subject to BTG intellectual property and license agreements.
BTG’s interventional medicine products, which use devices to deliver drugs to affected organs, would augment its capabilities in important areas of unmet need such as cancer and pulmonary embolism.
The company has long produced drugs to treat overdoses and rattlesnake bites, has focused on interventional medicine in recent years, for example producing beads that target tumors
BOTH BOARDS ARE HAPPY
The transaction has been unanimously approved by the boards of directors of Boston Scientific and BTG.
“The acquisition of BTG and its rapidly growing peripheral interventional portfolio is an exciting extension of our category leadership strategy that will augment our capabilities in important areas of unmet need such as cancer and pulmonary embolism,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific.
“We are confident that the addition of these therapies to our portfolio will ultimately advance patient care in ways that could not be realized by either company alone, while also allowing us to realize substantial revenue and cost synergies and provide a strong return for investors.”
Louise Makin, chief executive officer of BTG, agreed with Mahoney.
“Boston Scientific shares our commitment to transforming patient care, and has a sustained track record of innovation, clinical expertise and global commercial capabilities,” Makin said.
“The combined organization will be well positioned for success, enabling our valuable products to make a real difference to more people around the world.” VTN